Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.
Carissa E ChuMartin SjostromEmily A EgusaEwan A GibbMichelle L BaduraJun ZhuVadim S KoshkinBradley A StohrMaxwell V MengRaj S PruthiTerence W FriedlanderYair LotanPeter C BlackSima P PortenFelix Y FengJonathan ChouPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Sensitivity to EV is mediated by expression of NECTIN4, which is enriched in luminal subtypes of bladder cancer. These findings may have implications for biomarker development, patient selection, and the inclusion of molecular subtyping in ongoing and future EV clinical trials.See related commentary by Teo and Rosenberg, p. 4950.